Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib

Alyse S Goldberg
Robert A Hegele

Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Correspondence: Robert A Hegele
Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, N6A 5K8
Tel +1 519 931 5271
Fax +1 519 931 5218
Email hegele@robarts.ca

Abstract: Among the noteworthy recent stories in the management and prevention of atherosclerotic cardiovascular disease (CVD) is the saga of the development of pharmacological inhibitors of cholesteryl ester transfer protein (CETP). Inhibiting CETP significantly raises plasma concentrations of high-density lipoprotein cholesterol, which has long been considered a marker of reduced CVD risk. However, the first CETP inhibitor, torcetrapib, showed a surprising increase in CVD events, despite a dramatic increase in high-density lipoprotein cholesterol levels. This paradox was explained by putative off-target effects not related to CETP inhibition that were specific to torcetrapib. Subsequently, three newer CETP inhibitors, namely dalcetrapib, anacetrapib, and evacetrapib, were at various phases of clinical development in 2012. Each of these had encouraging biochemical efficacy and safety profiles. Dalcetrapib even had human arterial imaging results that tended to look favorable. However, the dalcetrapib development program was recently terminated, presumably because interim analysis of a large CVD outcome trial indicated no benefit. These events raise important questions regarding the validity of the mechanism of CETP inhibition and the broader issue of whether pharmacological raising of high-density lipoprotein cholesterol itself is a useful strategy for CVD risk reduction.

Keywords: dalcetrapib, CETP inhibitor, HDL, cardiovascular disease

Background

Despite the success of statin therapy in targeting low-density lipoprotein (LDL) cholesterol to reduce cardiovascular disease (CVD) event rates by 30%–40%, CVD risk has not been abolished with statin treatment. Low serum concentration of high-density lipoprotein (HDL) cholesterol (<0.9 mmol/L) is considered by many to be the strongest lipid risk factor for CVD and coronary artery disease. Epidemiological studies consistently suggest that a 0.26 mmol/L increase in HDL cholesterol level is associated with 2%–3% decrease in CVD events. This possible role of HDL cholesterol in explaining the residual risk among patients who suffer CVD events despite achieving target LDL cholesterol levels has led to interest in targeting biochemical pathways to increase HDL cholesterol. One such mechanism is inhibition of cholesteryl ester transfer protein (CETP). The purpose of this paper is to address the role of CETP-targeted therapy for reducing CVD risk, with the focus on the case of dalcetrapib, the development of which was recently terminated.

HDL particles

The major structural proteins that form the scaffold for HDL are apolipoprotein (apo) A-I and apo A-II. The heterogeneous subpopulations of HDL particles vary in
Drug design, development, and therapy

HDL begins its life cycle as a small, flat, lipid-poor discoidal particle, termed pre-β HDL, which is secreted directly from the liver or intestine or which can be assembled in the plasma (Figure 1). At the surface of peripheral cells, cholesteryl ester (CE) and free cholesterol are transported from the cell interior to the small nascent HDL particles by ATP-binding cassette subfamily members G1 and A1, respectively. The action of lecithin-cholesterol acyltransferase on these lipid substrates results in enlargement and maturation of spherical HDL particles, which journey back to the liver and constitute the predominant form of circulating HDL. Density-based ultracentrifugation divides these larger HDLs into HDL₂ and HDL₃ subfractions, with HDL₂ being larger and less dense than HDL₃.

Two broad types of atheroprotective mechanisms have been attributed to HDL: (1) its role in reverse cholesterol transport (RCT) and (2) its multiple beneficial “pleiotropic effects,” including protecting against oxidative stress and inflammation and promoting endothelial repair and function.

HDL functionality

When HDL cholesterol is measured clinically, the reported value does not directly reflect the number or type of particles, but rather it indicates the amount of cholesterol that is contained within the entire HDL lipoprotein fraction. There is no information provided on how the cholesterol is distributed among the various HDL subfractions, nor is there any implication for the HDL function, for instance, its role in RCT or its multiple pleiotropic effects.

It appears that not all HDLs are equally functional and that distinct subpopulations have different cardioprotective properties. For instance, among the HDL particles distinguished by ultracentrifugation, HDL₂ – the larger, less dense HDL – may be particularly important at some stages of RCT, and in some studies, its concentration is the best negative predictor of CVD events. These particles are also inversely correlated with atherosclerosis, hypertriglyceridemia, and CVD. In contrast, the smaller, denser HDL₃ subfraction may protect LDL from oxidative stress, while very small particles, such as pre-β HDL, are more functionally active in RCT. Fractions that can be distinguished on gradient gels also appear to have functional differences.

Figure 1 HDL lifecycle and CETP function.

Notes: Pre-β HDL (lipid-poor apo A-I HDL particles) is converted to spherical HDL₃ by lecithin-cholesterol acyltransferase (LCAT). HDL₃ is converted to HDL₂ by fusion of small HDL particles activated by phospholipid transfer protein (PLTP). The modulator role of CETP transfers cholesteryl esters (CE) between HDL particles to create both larger HDL₂ and smaller pre-β HDL particles (green arrows), which may be an antiatherogenic process. CETP also mediates heterotropic transfer of triglyceride between LDL/VLDL and HDL (orange arrows), as discussed in the text.

Abbreviations: CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein.
lower α-1 and pre-α-1 but higher α-3 HDL subfractions are evident in patients with CVD,$^5$ and low α-1 and α-2 levels predict CHD.$^{14,15}$ However, these differential functions attributed to specific subclasses of HDL are largely in vitro phenomena, as yet with little direct correlation with CVD surrogate endpoints.$^6$

### Multiple means of raising HDL

Current modes of increasing HDL include lifestyle changes (such as weight loss, smoking cessation, reducing intake of trans and saturated fats, and increasing exercise) and certain medications – in particular, fibrates and niacin. In addition to raising HDL cholesterol levels, all of these modalities have the added benefit of decreasing plasma triglyceride (TG) levels,$^6,17$ a biochemical effect that has not been demonstrated consistently with CETP inhibition. Moderate alcohol intake also can raise HDL cholesterol, but often increases TG levels concurrently; because alcohol is an addictive substance, it is not typically advised as a “lifestyle” means of raising HDL cholesterol.

Among existing pharmacotherapies, fibrates have a relatively small effect on HDL cholesterol levels (an approximately 10% increase), while the impact of niacin is greater (an approximately 25% increase, or more at the highest doses). Niacin’s HDL-raising effect has been known for at least 50 years, and this has always been considered beneficial. However, niacin’s role in preventing CVD by increasing HDL cholesterol was recently called into question after the premature stopping of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial because of its futility.$^{18}$ The possible reasons for this disappointing outcome include a higher-than-expected HDL cholesterol increase in the control group and very low levels of LDL cholesterol associated with longstanding pre-treatment with statin drugs in both treatment groups. This might have left minimal unstable lipid-rich plaques remaining that could benefit from HDL raising. Also, the sample size, in retrospect, was relatively small (approximately 3400 patients), and the study was likely statistically too underpowered to detect hard significant differences in CVD outcomes. Mechanistically, niacin has been shown to be associated with increased α-1 HDL levels, which should be of benefit.$^{19}$ Optimism thus persists for the very large Heart Protection Study 2 (HPS2-THRIVE), scheduled to report in 2013, which has enrolled approximately 25,000 patients and should provide the definitive word on the clinical efficacy of extended-release niacin in CVD risk reduction.$^{20}$

### CETP

Circulating CETP is produced by the liver and is bound to small HDL particles and nascent discoid-shaped HDL (Figure 1.$^{21}$ In plasma, CETP facilitates the exchange of CE from HDL for TG from apo B-containing lipoproteins, which include LDL, intermediate-density lipoprotein, and very low density lipoprotein. This “heterotropic” exchange, or “heterotransfer,” results in CE-enriched apo B particles and HDL particles with high TG content. Further, the HDL particles that are derived from CETP activity are small and can be renally excreted, resulting in low HDL cholesterol levels. However, the net result of lowering HDL cholesterol and increasing LDL cholesterol led to the concept that inhibiting CETP would result in a favorable LDL:HDL cholesterol ratio, which in turn would slow atherogenesis and reduce clinical events.$^2$ The CETP-related increase in the CE content of atherogenic apo B-containing lipoproteins may not be deleterious in the context of the normal physiological capacity for LDL-particle uptake and catabolism.

### CETP modes of action

CETP may contribute to both HDL atheroprotective mechanisms. For instance, as part of RCT, CETP plays a critical role in transferring to apo B-containing lipoproteins CE that originated from peripheral tissues, driving uptake and disposal of cholesterol by the liver.$^3$ Also, inhibition of CETP blocks this transfer and can lead to an accumulation of HDL particles, which should also be beneficial, since these particles are proposed to have multiple beneficial effects on vascular biology, inflammation, and coagulation.

Ultimately, the goal of CETP inhibition is to increase plasma-HDL cholesterol and thereby reduce CVD risk. Interestingly, reduced CVD risk has been observed less than consistently among patients with naturally occurring CETP mutations, providing a clue that reduced CETP activity is not automatically favorable.$^{22}$ However, CETP also transfers lipids between HDL subspecies through a process called “homotransfer,” which remodels HDL and raises levels of certain subspecies, including HDL$_2$ and a smaller pre-β-HDL from HDL$_3$. $^{21}$ HDL remodeling also permits apo A-I to accept CE from ATP-binding cassette subfamily member A1,$^4$ a process that has antiatherogenic potential. However, the balance in vivo between these manifold mechanisms and the predicted integrated effects of CETP inhibition are not clear-cut.

The subtleties of HDL structure and function might clarify both the complexity and the sometimes counterintuitive effects of CETP inhibition on clinical outcomes.
Further, different CETP inhibitors have different effects on heterotransfer of lipids between HDL and apo B-containing lipoproteins and on homotransfer, among other differences in effects. Understanding the intricacies of what differentiates the various CETP inhibitors thus requires a deeper appreciation of HDL structure and function.

**Past and present CETP inhibitors for dyslipidemia**

Torcetrapib (Pfizer Inc, New York, NY) was the first CETP inhibitor to progress to Phase III clinical trials. Initially, animal studies were encouraging: they demonstrated that torcetrapib increased HDL cholesterol concentrations approximately three-fold and reduced atherosclerotic plaque by 60%.

In humans, increases in HDL cholesterol of up to 91% were seen with monotherapy, and up to 60% reductions were seen with concurrent use of statins, sparking great enthusiasm for this therapeutic strategy; this was, however, tempered by early recognition of a modest effect on blood pressure, with increases of 1.3–2.2 mmHg in systolic blood pressure and 0.9–1.1 mmHg in diastolic blood pressure at doses of 60 or 90 mg/day. Also, approximately 4% of individuals showed a >15 mmHg increase in blood pressure, but most opinion leaders at the time considered this to be of only marginal clinical importance, compared with the lipid-modulating benefits of torcetrapib.

Unfortunately, the mood abruptly changed in 2006 when a pivotal large-scale clinical trial, namely Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events (ILLUMINATE), was prematurely discontinued after torcetrapib was associated with an increased risk of CVD events and death, despite a 72% increase in HDL cholesterol and a 25% decrease in LDL cholesterol levels. The concurrent cardiovascular surrogate outcome trials, including ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Atherosclerosis by CETP Inhibition and HDL Elevation), RADIANCE-1 (Rating Atherosclerosis Disease Change with a New CETP Inhibitor), and RADIANCE-2, all showed no change in coronary or carotid atherosclerosis, and no differences in regression of atherosclerosis in patients who received torcetrapib. Subsequent post hoc analysis did rekindle hope, as some patients from ILLUSTRATE, who were treated with torcetrapib and were within the highest quartile of HDL cholesterol increase, actually showed regression in coronary plaques.

The clinical failure of torcetrapib has subsequently been attributed to “off target” effects on aldosterone and cortisol levels, electrolytes, blood-pressure changes, and prolongation of QT interval on the electrocardiogram. But some still consider that a cleaner drug – one with pure CETP inhibition that is independent of off-target effects – could still be an effective therapeutic approach. However, the question remains as to whether the mechanism of CETP inhibition is not itself therapeutically beneficial: perhaps CETP inhibition generates large amounts of large HDL particles that are not optimally functional. Nevertheless, to avoid another failure similar to that of torcetrapib, development of the subsequent CETP inhibitors anacetrapib (Merck and Co, Inc, Whitehouse Station, NJ), evacetrapib (Eli Lilly and Company, Indianapolis, IN), and dalcetrapib (Roche, Basel, Switzerland) included early safety monitoring, with especially close attention paid to changes in blood pressure.

**Anacetrapib and evacetrapib**

Anacetrapib appears to be the most potent CETP inhibitor; it reduces CETP activity by up to 90% within 24 hours. As a result, it has impressive HDL cholesterol-raising and LDL cholesterol-lowering capabilities both as monotherapy and in combination with a statin. In the DEFINE study, designed to assess the efficacy and safety of anacetrapib, Cannon et al conducted a multicenter, randomized, double-blind, placebo-controlled trial, and showed that LDL cholesterol was reduced by 36%, that HDL cholesterol was increased by 139%, and that there was no effect on TG in patients with anacetrapib together with a statin. No significant effect on high-sensitivity C-reactive protein was seen with anacetrapib monotherapy. Meanwhile, dose-dependent decreases in lipoprotein(a) (Lp[a]) of up to 50% were observed, which is another potential benefit. Regarding safety, many studies have shown that the deleterious effects of torcetrapib – such as increases in blood pressure, plasma corticosterone, and aldosterone, and increased induction of two steriodogenic enzymes (CYP11B1 and CYP11B2) involved in the last step of cortisol and aldosterone biosynthesis – are not seen with anacetrapib. Overall, to date, anacetrapib has been generally well tolerated clinically, with no evidence of blood-pressure elevations.

A more recent addition to the CETP-inhibitor family is evacetrapib. Similar to anacetrapib, early-phase clinical trials with evacetrapib were promising, with no effects on blood pressure or aldosterone levels. When administered in the presence of a statin to patients with dyslipidemia, 100 mg evacetrapib inhibited CETP activity by 89%, reduced LDL cholesterol by approximately 12%, and increased HDL cholesterol by approximately 80%. Additionally, evacetrapib had no effect on high-sensitivity C-reactive protein,
blood pressure, or aldosterone levels. Unique to evacetrapib was a significant reduction in TG levels, especially at the 500 mg daily dose.

While anacetrapib and evacetrapib have provided encouraging clinical results, many questions still remain. To date, there have been no endpoint studies on anacetrapib or evacetrapib, although these are underway. Additionally, the integrated effects of these agents on HDL subclasses and composition, and especially on HDL functionality, are unclear.

Dalcetrapib: pharmacology
Among the CETP inhibitors, dalcetrapib appeared to have a distinctive mechanism of action and thus effect on clinical variables. Specifically, the increases in HDL cholesterol concentrations were much less pronounced with dalcetrapib (approximately 30% with the 600 mg dose) than with either anacetrapib or evacetrapib (approximately 120%–130% at full doses). Also, dalcetrapib had little effect on LDL cholesterol, in contrast to the LDL lowering of up to 40% seen with the other agents.

The earlier observation that torcetrapib treatment led to CE accumulation in HDL and selectively increased the level of spherical HDL particles provided a clue to the possible mechanistic differences between dalcetrapib and the other CETP inhibitors. Rather than the virtually complete inhibition of CETP’s transfer function seen with the other agents, dalcetrapib is a weaker inhibitor. This supported the concept that dalcetrapib was a CETP modulator rather than a full CETP inhibitor. Further, dalcetrapib was postulated to induce a conformational change in CETP allowing the transfer of CE from HDL₃ to HDL₂ and preserving the formation of pre-β HDL particles. So while it raised HDL cholesterol considerably less than the other CETP inhibitors, the apparent selectivity of dalcetrapib for homotransfer of CE among HDL particles raised hope and expectations for a preferential antiatherogenic function. In contrast, the heterotransfer of CE between HDL and apo B-containing lipoproteins, which characterizes the other CETP inhibitors, could have explained why torcetrapib had no effect on atheroma and a negative effect on outcomes. In animal studies, it appears that HDL particles that are formed secondarily to treatment with dalcetrapib, but not necessarily with anacetrapib, promote RCT and in vitro efflux of cholesterol from macrophages. These studies also showed differential effects of these agents on HDL subpopulations, as only anacetrapib inhibited transfer of CE from HDL₃ to HDL₂ and also formed pre-β HDL particles. Based on these findings, there was considerable optimism regarding dalcetrapib, and Roche undertook a major comprehensive program of clinical trials.

Safety and tolerability of dalcetrapib
After the failure of torcetrapib, concerns over a “class effect” on adverse outcomes led to stringent monitoring of the safety and efficacy of subsequent CETP-targeting agents. In early studies, dalcetrapib was found neither to cause hypertension in rats nor to increase expression of the renin-angiotensin-aldosterone-system mRNA in the adrenal glands and aortas of rats. Importantly, the absence of any blood-pressure effects and aldosterone secretion was also seen in humans after 4 weeks.

Other adverse effects beyond the anticipated blood-pressure changes were also studied. Dalcetrapib had no effect on the cardiac QT interval in healthy subjects following multiple dosing regimens. No changes in mesenteric lymph nodes as measured by MRI were seen in patients on dalcetrapib. In the Phase I studies administering high-dose dalcetrapib to healthy men, Derks et al reported no serious adverse events. In the four-week-long Phase II trial by Stein et al, the only adverse events of dalcetrapib compared to placebo were seen only in patients receiving high doses (900 mg), and they included only gastrointestinal symptoms. Dalcetrapib also has minimal interactions with other medications, including statins and ezetimibe, and was even tolerated when coadministered with ketoconazole, a cytochrome P450 3A4 inhibitor.

Efficacy of dalcetrapib and comparative studies
Early clinical studies of dalcetrapib demonstrated positive results on biochemical and surrogate outcomes. de Grooth et al showed, in 198 patients with mild hyperlipidemia, that dalcetrapib at doses from 300 to 900 mg for 4 weeks decreased CETP activity by up to 37%, increased HDL cholesterol by 34%, decreased LDL cholesterol by 7%, and had no effect on TG. Subsequent studies also showed biochemical efficacy. For instance, Kuivenhoven et al and Hermann et al showed a 28% and 26% respective increase in HDL cholesterol with the 600 mg daily dose. Hermann et al also demonstrated a fall in TG by 22%, as well as an increase in brachial flow-mediated dilation (FMD), a presumed representation of endothelial function, when patients with low baseline HDL cholesterol were on dalcetrapib treatment. However, no changes to FMD or to serum markers of inflammation were seen with dalcetrapib treatment, overall. Finally, Stein et al
conducted Phase II trials evaluating efficacy at 4 weeks and 12 weeks. These demonstrated that dalcetrapib treatment increased HDL cholesterol by up to 36%, setting the stage for the large clinical trials.

The dal-HEART program

The optimism for and commitment to dalcetrapib were underscored by embarking on the Dalcetrapib HDL Evaluation, Atherosclerosis and Reverse Cholesterol Transport (dal-HEART) program, which was comprised of a series of double-blind, randomized, placebo-controlled studies assessing hard clinical outcomes and some imaging markers. The dal-HEART program included five principal studies, specifically dal-PLAQUE, dal-VESSEL, dal-PLAQUE2, dal-ACUTE, and dal-OUTCOMES.

Dal-PLAQUE was a Phase IIIB double-blind, randomized, placebo-controlled study, which showed that dalcetrapib treatment reduced the increase in vessel plaque area in patients already on statin therapy. The study assessed the effect of dalcetrapib (600 mg daily) versus placebo on atherosclerotic plaque in 130 subjects with high coronary artery disease risk. In addition, the presence of vessel wall thickening was measured by positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI). One hundred and thirty patients received either dalcetrapib or placebo for up to 2 years. Eighty-six percent of the subjects were taking statins and had an LDL cholesterol level of less than 2.6 mmol/L. Primary endpoints were assessed by MRI of plaque size and PET/CT scanning of target-plaque-to-background-blood ratio. The authors observed a significant difference ($P < 0.04$) in the progression of plaque in the dalcetrapib group compared to the placebo group as assessed by MRI. Although a 7% reduction in the most diseased carotid segment was seen in the dalcetrapib group, no significant difference ($P = 0.08$) in the wall thickness of the right and left carotid arteries or the ascending thoracic aorta was found when measured by PET/CT.

Overall, dal-PLAQUE found that dalcetrapib was safe and possibly led to regression of carotid lesions and reduction of vessel inflammation. These mild changes observed must be interpreted in context, as the patients were concurrently on effective statin therapy, illustrating that the plaque benefit was incremental to that of statins. Interestingly, these benefits correlated with the degree of HDL cholesterol increase. The dalcetrapib group also showed a 7% reduction in LDL cholesterol beyond that accounted for by their statin treatment. Although not powered statistically to look at CVD events, in dal-PLAQUE there were fewer CVD events in the dalcetrapib group than in the placebo group (3% vs 11%, respectively).

In the recent dal-VESSEL trial, patients with CVD or equivalent and low HDL cholesterol were treated with dalcetrapib 600 mg or placebo for 36 weeks. Here, the primary endpoints evaluated were the change in brachial FMD after 12 and 36 weeks. Similar to prior studies, dalcetrapib treatment led to a 50% reduction in CETP activity and a 31% increase in HDL cholesterol. Levels of apo A-I were also increased, but there was no change to LDL cholesterol. Despite these favorable biochemical changes, no significant differences were observed for FMD at any point of the study. Ambulatory 24-hour systolic and diastolic blood pressures at 4, 12, and 36 weeks were not altered in the dalcetrapib arm, and there were no increases in nitric oxide-dependent endothelial function or markers of oxidative stress and inflammation.

Unpublished studies in the dalcetrapib clinical program include dal-PLAQUE2, dal-ACUTE, and dal-OUTCOMES. Dal-PLAQUE2 was designed to evaluate dalcetrapib’s effect on atherosclerosis by measuring coronary plaque in 900 patients by intravascular carotid B-mode ultrasound imaging and coronary angioplasty. Dal-ACUTE (NCT01323153) evaluated the use of dalcetrapib in 300 patients after acute coronary syndrome. The largest study, namely dal-OUTCOMES, was a multicenter, randomized, double-blinded, placebo-controlled Phase III trial that randomized 15,600 patients to either dalcetrapib or placebo 4 to 12 weeks after acute coronary syndrome. Patients were monitored for major cardiovascular events, including coronary artery disease death, acute MI, unstable angina requiring hospital admission, cardiac arrest, or stroke. In May 2012, Roche announced that it was terminating the dal-OUTCOMES trial 2 years early due to its lack of efficacy, and was simultaneously terminating the entire dalcetrapib program.

Implications of termination of the dalcetrapib development program

The CVD prevention community has been left somewhat shell-shocked after the recent turn of events related to dalcetrapib, which, to say the least, were unexpected and surprising. Dalcetrapib lacked the known off-target effects of torcetrapib. Further, dalcetrapib’s contribution to the reduction of atherosclerotic progression and vascular inflammation without adversely affecting blood pressure or aldosterone seemed encouraging. But despite these encouraging safety and efficacy signals from the early-phase clinical trials, and the evidence favoring the unique mechanism of CETP modulation, the Phase III dal-OUTCOMES trial
was terminated prematurely.\textsuperscript{62} Full details surrounding this termination should emerge soon, and hopefully there will be full publication of them. However, the termination appears to have been due to lack of efficacy rather than to increased risk of harm or deleterious effects.\textsuperscript{63}

Considering the prior failures of ILLUMINATE and AIM-HIGH, dal-OUTCOMES adds further evidence that targeting HDL does not improve CVD risk. But is the HDL hypothesis wrong? Or does the way in which HDL is raised matter? Perhaps CETP inhibition is not the best way to raise HDL. Further evidence that HDL itself may simply be a biomarker rather than a causal factor for CVD came from recent genetic studies performed in tens of thousands of patients, which found (1) an inverse association of CHD risk in patients with genetically reduced CETP function\textsuperscript{64} and (2) that certain genetic variants that raise HDL over a lifetime do not lower risk of myocardial infarction.\textsuperscript{65} Although these results seem to further undermine the importance of HDL, it may be too soon to bury HDL as a target for treatment.

Certainly, serum HDL cholesterol level is an exemplary biomarker and risk predictor. But that does not automatically make it a therapeutic target. We are beginning to appreciate that it is perhaps the quality and function of HDL, or more likely of a specific HDL subfraction, that may be mechanistically more important in causing CVD. In other words, not all HDL particles are equally protective, and current clinical assays that simply measure the total quantity of HDL cholesterol cannot assess these qualitative functional differences. It remains unclear which, if any, of HDL’s many roles give protection from cardiovascular effects, since its anti-inflammatory, antioxidant, anti-thrombotic,\textsuperscript{7} and other functional properties are still under investigation.

Epidemiological studies have shown that low HDL does confer an increased risk of CVD,\textsuperscript{2} and there have been reports that pharmacologic CETP inhibition does not impair the lipid-mobilizing activities of HDL.\textsuperscript{66} However, pharmacologically raising HDL has yet to show benefits in those at residual risk of CVD. It has not yet been proven that there is a causal relationship between HDL cholesterol level and cardio-protection, and low HDL cholesterol may be simply a marker of other disease processes.

Although the “HDL hypothesis” has been weakened lately, it is worth noting that large-scale outcome studies of anacetrapib and evacetrapib are ongoing and have not been terminated. Furthermore, other types of CETP inhibitors are under development.\textsuperscript{67} To date, the effects of anacetrapib and evacetrapib on the progression of atherosclerosis or CVD endpoints are unknown, but both profoundly increase HDL cholesterol, compared to dalcetrapib. Perhaps as important, anacetrapib and evacetrapib also reduce LDL cholesterol by 35\%–40\%. So it is a distinct possibility that CVD outcome trials with anacetrapib and evacetrapib added to statins will show a benefit, but this may not have anything to do with the effect on HDL. The experience with dalcetrapib provides few clues to help predict the outcomes of trials with the remaining CETP inhibitors. These are important studies that might finally settle the debate over whether either HDL raising or CETP inhibition are useful approaches to CVD risk reduction.

Disclosure
Dr Hegele is a Career Investigator of the Heart and Stroke Foundation of Ontario, holds the Edith Schulich Vinet Canada Research Chair (Tier I) in Human Genetics, the Martha G Blackburn Chair in Cardiovascular Research, and the Jacob J Wolfe Distinguished Medical Research Chair at the University of Western Ontario. This work was supported by CIHR (MOP-13430, MOP-79523, CTP-79853), and by the Heart and Stroke Foundation of Ontario (NA-6059, T-6018, PRG-4854). The authors report no other conflicts of interest in this work.

References


